New hope for tough blood cancers: drug combo aims to stop relapse after transplant
NCT ID NCT04708054
Summary
This study is testing if adding a drug called venetoclax to a standard chemotherapy and stem cell transplant regimen works better for adults with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if this combination helps control the cancer longer and prevents it from coming back after the transplant. Researchers will compare the new combination against the current standard treatment to see which is more effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.